Recent Updates — EYPT
Following a Phase 3 clinical trial failure for its lead drug candidate DURAVYU in wet age-related macular degeneration (wet AMD), EyePoint's Board approved a strategic prioritization plan to reduce operating expenses and preserve capital. The company will conclude the pivotal LUCIA trials early and cut approximately 53% of its workforce, with reductions occurring primarily in Q4 2026 and completing by H1 2027. This restructuring is expected to generate annualized savings of $30 million but will incur one-time aggregate charges of approximately $9 million for employee separation benefits. EyePoint will now focus resources on the late-stage development of DURAVYU for diabetic macular edema (DME), with pivotal data expected in Q4 2027. The company reported preliminary cash and short-term investments of $118 million as of September 30, 2026. EyePoint is a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.
EyePoint announced topline results from the LUCIA pivotal Phase 3 clinical trial evaluating DURAVYU for wet age-related macular degeneration. The study failed to meet its primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity versus on-label aflibercept control, despite demonstrating visual improvement and a favorable safety profile with redosing. Key secondary endpoints were met, including a 38% reduction in treatment burden and strong anatomic control at Week 56. The company plans additional analyses of the LUCIA and pooled Phase 3 datasets to assess next steps for wet AMD. Meanwhile, the pivotal Phase 3 DME program remains on track, with topline data from the COMO and CAPRI trials expected in the fourth quarter of 2027. EyePoint is a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.
EyePoint announced topline data from the LUGANO Phase 3 trial for DURAVYU in wet AMD. The primary endpoint was not achieved in the full dataset due to an asymmetric cohort of nine patients experiencing vision loss unrelated to wet AMD. However, an ad hoc analysis excluding this group showed non-inferiority versus aflibercept (p=0.0096). Key secondary endpoints were met, including a 42% reduction in treatment burden and superior supplement-free rates. The company plans to report LUCIA data in Q4 2026 and submit an NDA in H1 2027. EyePoint is a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases.
EyePoint, Inc. reported second quarter 2026 financial results showing total net revenue of $0.5 million and a net loss of $94.5 million, or ($1.09) per share, compared to $5.3 million in revenue and a $59.4 million net loss in the prior year period. Operating expenses increased to $97.9 million from $67.6 million due to ongoing Phase 3 clinical trials for DURAVYU and manufacturing scale-up. The company holds $180 million in cash and investments, providing operational runway into the fourth quarter of 2027. Clinically, top-line data for the pivotal Phase 3 LUGANO wet AMD trial is expected in August 2026, with LUCIA following in Q4 2026; DME trials COMO and CAPRI are fully enrolled with topline data anticipated in Q4 2027. EyePoint, Inc. operates as a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.
EyePoint, Inc. announced the completion of enrollment in two pivotal Phase 3 clinical trials, COMO and CAPRI, evaluating DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME). The company enrolled over 480 participants across both global trials within five months, ahead of schedule. Topline data from these DME studies is anticipated in the fourth quarter of 2027. This milestone follows a Data Safety Monitoring Committee review that recommended continuing both the DME and wet AMD Phase 3 programs without protocol modifications. EyePoint, Inc. operates as a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.